News >

Ibrutinib and Idelalisib Continue to Impress in CLL, May Eventually Replace Chemotherapy for Some Patients

Gina Columbus @ginacolumbusonc
Published: Tuesday, Apr 28, 2015

Dr. Steven E. Coutre

Steven Coutre, MD

The efficacy of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients, according to Steven Coutre, MD, a professor of Medicine (Hematology) at Stanford University Medical Center.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication